Novo Nordisk Switzerland’s Mads Stoustrup introduces the affiliate’s remarkable process on bringing innovative diabetes and obesity treatments to market in the past four years, the road still to travel to ensure better outcomes for chronic disease patients in Switzerland, and the leadership he hopes to cultivate during the COVID-19 pandemic and beyond.
2020 has been very challenging for all of us. However, it has also been a year of reflection on what I am doing personally and what we are doing as a company
